BioCryst Pharmaceuticals, Inc.
Human plasma kallikrein inhibitors
Last updated:
Abstract:
Disclosed are compounds of formula I ##STR00001## as described herein, and pharmaceutically acceptable salts thereof. The compounds are disclosed to be inhibitors of plasma kallikrein. Also provided are pharmaceutical compositions comprising at least one compound of the invention, and methods involving use of the compounds and compositions of the invention in the treatment and prevention of diseases and conditions characterized by unwanted plasma kallikrein activity.
Status:
Grant
Type:
Utility
Filling date:
24 Mar 2020
Issue date:
7 Dec 2021